【摘要】 目的用表面增强激光解析离子化飞行时间质谱技术(SELDI-TOF-MS)建立肺腺癌病人血清蛋白质组构型,筛选相对特异标记物,并探讨其与病理分期的关系。方法肺腺癌病人71例,均经手术病理证实;正常人71名,按照性别,年龄,吸烟史与71例肺腺癌病人配对。用WCX2芯片检测各血清标本,筛选肺腺癌相对特异性蛋白质峰,并分析肺腺癌相对特异性蛋白与病理分期的关系。结果与正常人比较发现5个肺腺癌显著高表达的潜在标记物,相对分子量分别为4047.79±1.60、4203.99±1.91、4959.81±2.13、5329.30±2.55和7760.12±4.11,其中分子量为4047.79±1.60和7760.12±4.11的肺腺癌相对特异性蛋白与病理分期呈正相关。结论SELDI-TOF-MS蛋白质质谱技术是一种快速、简便易行且高通量的分析方法,能直接筛选出肺腺癌病人血清中相对特异的潜在标记物。更多还原

【Abstract】 Objective To select relatively specific biomarkers in serum from lung adenocarcinoma patients using surface-enhanced laser desorption and ionization time of flight mass spectrometry (SELDI-TOF-MS) ProteinChip technology, and clarify its’ correlation with patients’ clinical stage. Methods Serum samples from 71 lung adenocarcinoma patients, 71 healthy volunteers with matched gender, age and history of smoking were analyzed using WCX2 PoteinChip to select potentially biomarkers. Proteomic spectra were generated by mass spectrometry. Results Five highly expressed potential biomarkers were identified with the relative molecular weights of 4?047.79±1.60, 4?203.99±1.91, 4?959.81±2.13, 5?329.30±2.55 and 7?760.12±4.11. The relative molecular weights of 4?047.79±1.60 and 7?760.12±4.11 significantly correlated with patients’ clinical stage. Conclusion SELDI-TOF-MS ProteinChip technology is a quick, easy, convenient, and high-throughput analyzing method capable of selecting several relatively specific, potential biomarkers from the serum of lung adenocarcinoma patients and may have attractive clinic value for the correct clinic decision.更多还原